Personalizing Prostate Cancer Therapy Using AI-based Predictive Biomarkers – Paul Nguyen
In a discussion with Alicia Morgans, Paul Nguyen highlights the advancing role of predictive biomarkers in prostate cancer tr [...]
Artera Multi-Modal AI Platform – Guiding Treatment Decisions in Men with Prostate Cancer – Andre Esteva & Felix Feng
Andre Esteva and Felix Feng join Alicia Morgans to discuss the Artera MMAI platform in prostate cancer intended to identify p [...]
Beyond the NCCN Localized Prostate Cancer Risk Category: The MMAI Prognostic Risk Stratification Model – Jonathan Tward
Jonathan Tward joins Alicia Morgans to discuss advancing prognostic capabilities in prostate cancer risk stratification using [...]
Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate Cancer – Daniel Spratt
Alicia Morgans and Daniel Spratt discuss an AI-derived multi-modal digital pathology-based biomarker test designed towards im [...]
Dr. Spratt Highlights the Validation of an MMAI Prognostic Biomarker for Prostate Cancer
Urology Times features a video of Daniel Spratt, MD discussing results demonstrating successful validation of ArteraAI’s MMAI [...]
Artificial Intelligence Transformative in Prostate Cancer Patient Care – Felix Feng
Felix Feng joins Alicia Morgans to discuss how the application of artificial intelligence (AI) is transformative in prostate [...]
Who is ARTERA? – Andre Esteva
Andre Esteva, CEO of ArteraAI joins Alicia Morgans in a discussion about ArteraAI, which has developed an artificial intellig [...]
Beyond Genomics: AI Informing Decision Making in Prostate Cancer – Ashley Ross
In this conversation, Alicia Morgans and Ashley Ross discuss the current clinical landscape of how risk is defined in localiz [...]